1-2 of 2
Timothy J. Inocencio
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Reducing Time Toxicity for Anti-B-Cell Maturation Antigen (BCMA) Bispecific Treatment: Evidence from Pivotal Single-Arm Trial Data on Teclistamab, Elranatamab, and Linvoseltamab for Triple-Class Exposed (TCE) Relapsed/Refractory Multiple Myeloma (RRMM)

Sikander Ailawadhi, Timothy J. Inocencio, Zheng-Yi Zhou, Michael K. Xu, Jack Eales, Michelle Little, Peter Quon, Qiufei Ma
Journal: Blood
Blood (2024) 144 (Supplement 1): 2271.
https://doi.org/10.1182/blood-2024-199182
Published: 2024
Journal Articles

Health-Related Quality of Life (HRQoL) Among Patients with Triple-Class Exposed Relapsed/Refractory Multiple Myeloma (RRMM) Treated with Linvoseltamab in Linker-MM1: Interim Assessment up to 36 Weeks of Treatment

James E. Hoffman, Naresh Bumma, Joshua Richter, Madhav V. Dhodapkar, Hans C. Lee, Attaya Suvannasankha, Christiane A. Houde, Joseph J. Maly, Mansi R. Shah, Rachid Baz, Swathi Namburi, Ka Lung Wu, Matthew Pianko, Jing Christine Ye, Suzanne Lentzsch, Rebecca Silbermann, Chang-Ki Min, Marie-Christiane Vekemans, Markus Munder, Ja Min Byun, Joaquín Martínez Lopez, Michelle DeVeaux, Cristina Ivanescu, Karen Rodriguez Lorenc, Glenn S. Kroog, Yariv Houvras, Timothy J. Inocencio, Lei Chi, James Harnett, Qiufei Ma, Sundar Jagannath
Journal: Blood
Blood (2023) 142 (Supplement 1): 3359.
https://doi.org/10.1182/blood-2023-179170
Published: 2023